Good outcome rate of 35% in IV-tPA-treated patients with computed tomography angiography confirmed severe anterior circulation occlusive stroke
- PMID: 24003051
- PMCID: PMC4374554
- DOI: 10.1161/STROKEAHA.113.001938
Good outcome rate of 35% in IV-tPA-treated patients with computed tomography angiography confirmed severe anterior circulation occlusive stroke
Abstract
Background and purpose: To determine the effect of intravenous tissue plasminogen activator (IV-tPA) on outcomes in patients with severe major anterior circulation ischemic stroke.
Methods: Prospectively, 649 patients with acute stroke had admission National Institutes of Health stroke scale (NIHSS) scores, noncontrast computed tomography (CT), CT angiography (CTA), and 6-month outcome assessed using modified Rankin scale. IV-tPA treatment decisions were made before CTA, at the time of noncontrast CT scanning, as per routine clinical protocol. Severe symptoms were defined as NIHSS>10. Poor outcome was defined as modified Rankin scale >2. Major occlusions were identified on CTA. Univariate and multivariate stepwise-forward logistic regression analyses of the full cohort were performed.
Results: Of 649 patients, 188 (29%) patients presented with NIHSS>10, and 64 out of 188 (34%) patients received IV-tPA. Admission NIHSS, large artery occlusion, and IV-tPA all independently predicted good outcomes; however, a significant interaction existed between IV-tPA and occlusion (P<0.001). Of the patients who presented with NIHSS>10 with anterior circulation occlusion, twice the percentage had good outcomes if they received IV-tPA (17 out of 49 patients, 35%) than if they did not (13 out of 77 patients, 17%; P=0.031). The number needed to treat was 7 (95% confidence interval, 3-60).
Conclusions: IV-tPA treatment resulted in significantly better outcomes in patients with severely symptomatic stroke with major anterior circulation occlusions. The 35% good outcome rate was similar to rates found in endovascular therapy trials. Vascular imaging may help in patient selection and stratification for trials of IV-thrombolytic and endovascular therapies.
Keywords: computed tomography angiography; ischemic stroke; thrombolysis; tissue plasminogen activator; treatment outcome.
Similar articles
-
Early and continuous neurologic improvements after intravenous thrombolysis are strong predictors of favorable long-term outcomes in acute ischemic stroke.J Stroke Cerebrovasc Dis. 2013 Nov;22(8):e590-6. doi: 10.1016/j.jstrokecerebrovasdis.2013.07.024. Epub 2013 Aug 15. J Stroke Cerebrovasc Dis. 2013. PMID: 23954601
-
Clinical and vascular outcome in internal carotid artery versus middle cerebral artery occlusions after intravenous tissue plasminogen activator.Stroke. 2002 Aug;33(8):2066-71. doi: 10.1161/01.str.0000021001.18101.a5. Stroke. 2002. PMID: 12154264
-
IV vs. IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion: a feasibility study.Neurocrit Care. 2009;11(1):76-81. doi: 10.1007/s12028-009-9204-1. Epub 2009 Mar 10. Neurocrit Care. 2009. PMID: 19277904 Clinical Trial.
-
The Massachusetts General Hospital acute stroke imaging algorithm: an experience and evidence based approach.J Neurointerv Surg. 2013 May;5 Suppl 1(Suppl 1):i7-12. doi: 10.1136/neurintsurg-2013-010715. Epub 2013 Mar 14. J Neurointerv Surg. 2013. PMID: 23493340 Free PMC article. Review.
-
Intravenous thrombolytic therapy in acute ischemic stroke: The art and science of treatment decision making.Ann Indian Acad Neurol. 2008 Jan;11(Suppl 1):S24-S29. Ann Indian Acad Neurol. 2008. PMID: 35721450 Free PMC article. Review.
Cited by
-
Efficacy and safety of Ginkgolide with intravenous alteplase thrombolysis in acute ischemic stroke with large vessel occlusion: a subgroup analysis of GIANT.Front Pharmacol. 2024 Aug 30;15:1452174. doi: 10.3389/fphar.2024.1452174. eCollection 2024. Front Pharmacol. 2024. PMID: 39281272 Free PMC article.
-
The role of P-selectin/PSGL-1 in regulating NETs as a novel mechanism in cerebral ischemic injury.Front Neurol. 2024 Jul 3;15:1442613. doi: 10.3389/fneur.2024.1442613. eCollection 2024. Front Neurol. 2024. PMID: 39022737 Free PMC article. Review.
-
Sex Differences in Severity and Risk Factors for Ischemic Stroke in Patients With Hyperlipidemia.Neurosci Insights. 2024 May 3;19:26331055241246745. doi: 10.1177/26331055241246745. eCollection 2024. Neurosci Insights. 2024. PMID: 38706531 Free PMC article.
-
Integrative Approaches in Acute Ischemic Stroke: From Symptom Recognition to Future Innovations.Biomedicines. 2023 Sep 23;11(10):2617. doi: 10.3390/biomedicines11102617. Biomedicines. 2023. PMID: 37892991 Free PMC article. Review.
-
Fibrin-Targeted Nanoparticles for Finding, Visualizing and Characterizing Blood Clots in Acute Ischemic Stroke.Pharmaceutics. 2022 Oct 10;14(10):2156. doi: 10.3390/pharmaceutics14102156. Pharmaceutics. 2022. PMID: 36297588 Free PMC article.
References
-
- NINDS Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581–1587. - PubMed
-
- Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–1329. - PubMed
-
- Bonita R, Beaglehole R. Recovery of motor function after stroke. Stroke. 1988;19:1497–1500. - PubMed
-
- Rankin J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J. 1957;2:200–215. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
